IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 233
EU - Europa 131
AS - Asia 43
OC - Oceania 11
SA - Sud America 3
AF - Africa 1
Totale 422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 224
GB - Regno Unito 72
IT - Italia 19
IN - India 16
DE - Germania 14
AU - Australia 11
CN - Cina 9
CA - Canada 8
BE - Belgio 5
JP - Giappone 4
FR - Francia 3
TR - Turchia 3
TW - Taiwan 3
AL - Albania 2
CL - Cile 2
EE - Estonia 2
FI - Finlandia 2
IE - Irlanda 2
NL - Olanda 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BR - Brasile 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 422
Salva come PNG Salva come JPEG
Città #
Ashburn 105
London 69
Redmond 21
San Francisco 21
Rome 17
Council Bluffs 13
Pune 13
Boardman 11
Seattle 9
Toronto 7
Washington 7
Los Angeles 6
Melbourne 5
Tokyo 4
Canberra 3
Haikou 3
Mol 3
Sydney 3
Taipei 3
Amsterdam 2
Dublin 2
Hanover 2
Hasselt 2
Helsinki 2
Lodz 2
New Delhi 2
North Liberty 2
Oklahoma City 2
Paris 2
Shenzhen 2
Tallinn 2
Tirana 2
West Jordan 2
Almaty 1
Berlin 1
Central District 1
Centurion 1
Charlotte 1
Chicago 1
Cleveland 1
Colombo 1
Columbia 1
Dhaka 1
Frankfurt am Main 1
Hicksville 1
Krasnoyarsk 1
Lisbon 1
Manila 1
Minsk 1
Naples 1
Quilpué 1
Reston 1
Riyadh 1
Rockville 1
Swansea 1
Totale 373
Salva come PNG Salva come JPEG
Nome #
Anthracycline Cardiotoxicity 14
Pharmacology of Cardio-Oncology 13
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 12
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 12
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 11
Doxorubicin irreversibly inactivates iron regulatory protein-1 and –2 in cardiomyocytes: evidence for distinct metabolic pathways and implication for iron-mediated cardiotoxicity of antitumor therapy 11
Matters of the heart: The case of TNF-alpha targeting drugs. 11
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 11
Anthracyclines 11
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 10
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 10
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 10
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 10
The concomitant management of cancer therapy and cardiac therapy 10
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 9
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 9
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 9
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 9
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 9
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 8
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 8
Doxorubicin degradation in cardiomyocytes 8
Cancer drugs and QT prolongation: weighing risk against benefit 8
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 8
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 8
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 8
Anthracycline Cardiotoxicity 8
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 7
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 7
What is cardiotoxicity? 7
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 7
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 7
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 7
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 6
Do you know pixantrone? 6
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 6
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 6
Cardiotoxicity of antitumor drugs 6
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 6
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 6
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 6
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 6
Pharmacological Foundation of Cardio-Oncology 5
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 5
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 5
Isavuconazole: case report and pharmacokinetic considerations 5
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 5
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 5
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 5
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 5
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 5
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 5
Predictors of early or delayed diastolic dysfunction after anthracyclines-based or nonanthracycline chemotherapy: a pharmacological appraisal. 5
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 4
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 4
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 4
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 4
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 4
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 4
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 3
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 3
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 3
The reality of pixantrone in real life 3
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 3
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 3
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 3
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 3
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 3
Minimal sampling colistin pharmacokinetics in critically ill patients 3
Molecular determinants of the reduced cardiotoxicity of epirubicin 3
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 2
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 2
Translating molecular mechanisms into clinical facts 2
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 2
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 2
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 2
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 2
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 1
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 1
Totale 489
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.597
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022197 0 4 0 0 0 0 1 80 3 0 4 105
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024246 5 33 8 12 35 124 4 16 2 7 0 0
Totale 489